History of Cannabis

Cannabis is among the oldest cultivated plants on Earth. Archaeological evidence from Jiahu in central China suggests hemp cord was being used as early as 8,000 BCE, making cannabis one of the first plants humans deliberately grew and processed. Ancient communities in what is now China and Taiwan used cannabis fibre to produce rope, textiles, and paper — practical applications that explain why a naturally psychoactive plant received careful cultivation and preservation long before its intoxicating properties were widely exploited.

Seeds and roots have been recovered from burial sites across Central Asia dating to 3,000 BCE, suggesting ritual or medicinal use alongside industrial applications. The geographic origin of Cannabis sativa is now generally placed in Central Asia — most likely in the region encompassing modern Kazakhstan, Uzbekistan, and northern Afghanistan — from which it spread east into China, south into India, and west along trade routes into the Middle East and eventually Europe.

The ancient world distinguished between fibre-producing low-THC plants and psychoactive varieties, though not in the clinical terms we use today. Historical records show that different communities cultivated different phenotypes depending on their primary use: textile production, food (hemp seeds are highly nutritious), medicine, or ritual intoxication. This diversity of application explains why cannabis spread so rapidly and completely across the ancient world — it offered something useful to nearly every culture it encountered.

The oldest written reference to cannabis as medicine is found in the legendary Chinese pharmacopoeia "Shennong Bencao Jing" (The Classic of Herbal Medicine), attributed to the mythical Emperor Shennong and compiled around 2,700 BCE, though the written text dates to the first century CE. It describes cannabis as treating gout, malaria, rheumatism, and absent-mindedness, and notes both its therapeutic and intoxicating properties — perhaps the first acknowledgement in recorded history that a substance can simultaneously heal and alter consciousness.

Chinese medicine integrated cannabis into its practice in complex ways. The leaves, flowers, seeds, and roots were each assigned different medicinal properties. Cannabis seeds — notably non-psychoactive — formed a significant part of the traditional Chinese diet and pharmacy for thousands of years, valued as a source of oil and protein. Hemp fibre dominated the Chinese textile industry for millennia, preceding both cotton and silk as a mass-market fabric.

The Chinese were also the first to develop paper from hemp fibre, a technological advancement of incalculable importance to human civilisation. Early Chinese paper dating to around 100 BCE was predominantly made from hemp, and the technology spread westward along the Silk Road, eventually reaching Europe. Every monastery, government, and court that relied on written records for the next millennium owed an indirect debt to cannabis cultivation.

Chinese historical texts also contain some of the earliest explicit references to recreational and ritual cannabis use, including accounts of shamanic practices in which cannabis smoke was used during ceremonies, most likely to facilitate trance states. These references become more frequent from around the first century CE onward, suggesting a gradual broadening of cannabis use from elite medicinal and ritual contexts to wider social practice.

India's relationship with cannabis is among the deepest and most spiritually integrated in human history. The ancient Sanskrit text known as the Atharvaveda, composed between 1500 and 1000 BCE, lists cannabis (referred to as "bhanga") as one of five sacred plants, identifying it as a source of happiness, a liberator from anxiety, and a gift bestowed on humanity by the god Shiva. This religious association with Shiva — one of the principal deities of Hinduism — gave cannabis a sacred status in Indian culture that has persisted for over 3,000 years.

Bhang — a preparation of cannabis leaves and flowers blended into a drink, often with milk, spices, and sweeteners — has been consumed in India continuously since at least the first millennium BCE. It is still legally sold and consumed during religious festivals, particularly Holi and Mahashivaratri, in many parts of India today. Bhang shops operate legally in several Indian states, representing one of the longest continuous legal cannabis traditions in the world.

Ayurveda, the ancient Indian system of medicine dating to around 600 BCE, incorporated cannabis extensively. Sanskrit medical texts describe cannabis (called "vijaya" — "the one who gives victory") as a treatment for pain, nausea, insomnia, vomiting, and muscle spasm. The sophisticated classification system of Ayurvedic medicine differentiated between cannabis preparations based on the part of the plant used, the method of preparation, and the desired therapeutic outcome — a level of pharmaceutical sophistication that would not appear in European medicine until the 19th century.

Sadhu holy men have incorporated cannabis smoking into their religious practice for centuries, viewing intoxication as a path to the dissolution of the ego and union with the divine — particularly with Shiva, who is traditionally depicted holding or consuming cannabis. This tradition continues to the present day, with Sadhus legally permitted to use cannabis for religious purposes throughout much of India.

Cannabis arrived in the Middle East through trade routes and the movements of nomadic peoples from Central Asia. The Scythians — a highly mobile Iranian-speaking people who dominated the Eurasian Steppe from the seventh to third centuries BCE — are among the best documented early cannabis users outside Asia. The Greek historian Herodotus, writing around 440 BCE, describes Scythian funeral rites in which hemp seeds were heated on red-hot stones inside a small tent, producing smoke that caused mourners to "howl with pleasure." Archaeological excavations of Scythian burial mounds have confirmed this account, uncovering hemp seeds, braziers, and tent poles consistent with the ritual Herodotus describes — the first physical archaeological evidence of intentional cannabis smoking.

Cannabis spread through the Middle East along the same trade routes that carried silk, spices, and ideas between Asia and the Mediterranean. References appear in Assyrian texts from the first millennium BCE, identifying it as used in ritual contexts and as medicine. The ancient Hebrews may have included cannabis — referred to as "kaneh bosm" — in the holy anointing oil described in Exodus, though this interpretation remains debated by biblical scholars.

In Africa, cannabis appears to have arrived from Asia via Arab traders sometime in the first millennium CE, spreading southward through the continent over subsequent centuries. By the time European explorers reached sub-Saharan Africa in the 15th century, cannabis was already established across most of the continent, used for medicine, ritual, and recreational purposes by communities throughout East and Central Africa. The diffusion of cannabis through Africa was so complete that it appears in virtually every sub-Saharan culture that European researchers documented.

Hemp — the low-THC fibre variety of cannabis — was a cornerstone of European medieval economies. Every major naval power from ancient Phoenicia to 18th-century Britain depended on hemp rope and sailcloth; a single large sailing ship required approximately 80 tonnes of hemp for its rigging, sails, and caulking. The word "canvas" itself derives from the Latin "cannabis." Charlemagne issued decrees in the ninth century requiring farmers under his authority to grow hemp, recognising its strategic military and economic importance.

Hemp paper dominated European literacy and communication from the moment paper technology arrived from China. Gutenberg's Bibles were almost certainly printed on hemp paper, and hemp paper was the primary writing substrate for documents, books, and maps throughout the medieval and early modern periods. The Magna Carta, the Declaration of Independence, and the U.S. Constitution were drafted on hemp paper. Benjamin Franklin established one of America's first paper mills using hemp fibre in 1728.

Hemp fibre competed with flax as the dominant textile fibre across Europe and was woven into everything from fine linen-like cloth to rough working garments. Hemp seed oil was used for lamp fuel, paint, lubricant, and as a dietary supplement. Hemp was arguably the most commercially important plant in the European world from roughly 800 CE to 1800 CE — a two-thousand-year dominance that ended only with the industrialisation of cotton production and the mechanisation of the cotton gin.

Psychoactive cannabis entered Europe gradually during this period, primarily through contact with the Islamic world. Arab physicians such as Ibn Sina (Avicenna, 980–1037 CE) documented cannabis's medicinal and psychoactive properties extensively, and this knowledge filtered into European medicine. By the 16th and 17th centuries, some European physicians were experimenting with cannabis preparations for pain and spasm, though recreational use remained limited compared to Asia and Africa.

Cannabis arrived in the Americas with European colonists. The Spanish brought hemp seeds to Chile as early as 1545, and English colonists brought them to Jamestown, Virginia in 1611. Hemp cultivation was so important to the colonial economy that several American colonies passed laws requiring farmers to grow it — refusal could result in fines. Hemp supplied rope, sails, and clothing to the colonial fleet and was accepted as legal tender in many jurisdictions.

The American Founding Fathers were hemp growers. George Washington cultivated hemp at Mount Vernon and wrote in his diary about separating male and female plants — a practice relevant to producing more resinous female flowers rather than purely fibre production, suggesting an awareness of cannabis beyond its industrial uses. Thomas Jefferson maintained hemp fields at Monticello and developed a hemp-threshing machine. Benjamin Franklin's hemp paper mills produced the paper on which the new nation wrote its founding documents.

In the 19th century, psychoactive cannabis arrived in North America through multiple channels. Mexican immigrants brought recreational marijuana smoking across the southern border, introducing it to working-class communities in Texas and the American Southwest. Caribbean labourers brought smoking traditions to port cities on the Gulf Coast. And simultaneously, medical cannabis arrived through the mainstream pharmaceutical system — cannabis preparations were widely sold in American pharmacies from the 1850s through the 1930s.

The 19th century also saw the first serious scientific investigation of cannabis in Western medicine. Irish physician William B. O'Shaughnessy, working for the East India Company in Calcutta, conducted the first systematic clinical trials of cannabis preparations on Western patients in the 1830s, publishing influential findings on its efficacy for muscle spasm, rheumatism, and rabies management. His work introduced cannabis tinctures to mainstream Victorian medicine, where they became among the most widely prescribed medications of the era.

The Victorian era represented the peak of cannabis's acceptance as a mainstream Western medicine. Following O'Shaughnessy's publications from India, cannabis tinctures and extracts appeared in the pharmacopoeias of Britain and the United States and were sold freely in pharmacies across both countries. Eli Lilly, Parke-Davis, Squibb, and other early pharmaceutical companies produced and sold cannabis preparations commercially.

The range of conditions treated with cannabis in 19th-century medicine reads like a comprehensive index of human suffering: pain of all types, muscle spasm, epilepsy, asthma, menstrual cramps, gonorrhoea, insomnia, anxiety, opium withdrawal, and migraine. Queen Victoria's personal physician, Sir J. Russell Reynolds, prescribed her cannabis for menstrual pain. Sir William Osler, often called the "father of modern medicine," recommended cannabis as the most effective treatment for migraine in his foundational medical textbook.

The patent medicine industry — essentially a largely unregulated pharmaceutical market for proprietary remedies — enthusiastically incorporated cannabis. Products like Piso's Cure, Chlorodyne, and numerous "soothing syrups" for children contained cannabis alongside other active ingredients. These products were sold through newspapers, pharmacies, and travelling salesmen across the English-speaking world, giving millions of ordinary people their first encounter with cannabis-derived medicines.

The standardisation problem proved to be cannabis medicine's fatal weakness in an era of advancing pharmaceutical science. Unlike opium, from which morphine had been isolated in 1804, cannabis proved resistant to isolation of a single active compound (THC would not be identified until 1964 by Raphael Mechoulam). Without a standardisable active ingredient, quality control was impossible, and therapeutic effects were inconsistent between preparations. This variability, combined with the rise of more precisely dosed synthetic alternatives, drove cannabis gradually out of mainstream medicine in the early 20th century.

The prohibition of cannabis in the United States unfolded through a combination of racial prejudice, political ambition, and journalistic sensationalism that bore little relation to evidence of harm. Mexican immigration following the 1910 Revolution introduced recreational marijuana smoking to the American Southwest, where it became associated with Mexican labourers and subsequently with fear and xenophobia during the economic anxiety of the Depression era.

Harry Anslinger, appointed commissioner of the newly created Federal Bureau of Narcotics in 1930, recognised cannabis prohibition as an opportunity to expand his bureau's authority and budget. Anslinger personally orchestrated a national campaign against "marihuana" (the Spanish spelling deliberately chosen to emphasise the drug's foreign character) that combined fabricated crime statistics with explicitly racist messaging. Letters in Anslinger's files describe cannabis as "the most violence-causing drug in the history of mankind" and link its use to violence by Mexican, Black, and Caribbean users in terms that were overtly racist.

The Marihuana Tax Act of 1937 effectively criminalised cannabis at the federal level, passing through Congress with minimal debate. The American Medical Association's testimony opposing the bill — arguing that cannabis had legitimate medical uses and that the evidence presented did not support prohibition — was largely ignored. Within a decade, state-level prohibition had followed in most jurisdictions.

The 1936 film "Reefer Madness" — originally financed by a church organisation as a cautionary tale and later acquired and distributed by exploitation filmmakers — became the defining cultural artefact of this era: a melodramatic depiction of cannabis users descending into violence, madness, and moral corruption within hours of their first cigarette. Though factually absurd, it crystallised the public narrative around cannabis that would persist for decades.

The 1960s transformed cannabis from a drug associated in mainstream culture with racial minorities and moral degeneracy into a symbol of generational rebellion, artistic liberation, and political dissent. The Beat Generation writers of the 1950s — Jack Kerouac, Allen Ginsberg, William S. Burroughs — had documented cannabis use as part of their bohemian lifestyle, but it was the explosion of the hippie counterculture in the mid-1960s that brought marijuana into mainstream youth culture across the Western world.

The association between cannabis and popular music in this era was complete and explicit. The Beatles smoked marijuana with Bob Dylan in 1964 — a meeting that Dylan himself credited with profoundly influencing the band's subsequent creative direction. Jimi Hendrix, The Rolling Stones, The Grateful Dead, and virtually every major rock act of the era were open cannabis users whose music was deeply influenced by the experience. "Purple Haze," "Rainy Day Women #12 & 35," "Got to Get You into My Life" — cannabis saturated the cultural output of the decade.

Political opposition to cannabis prohibition became inseparable from opposition to the Vietnam War. Young people who had grown up consuming marijuana viewed its criminalisation as evidence of systemic government dishonesty — if officials would lie about cannabis, what else were they lying about? The Le Dain Commission in Canada (1972) and the Shafer Commission in the United States (also 1972) both recommended cannabis decriminalisation following extensive review, finding that the social and health harms of prohibition exceeded those of the drug itself.

President Nixon famously rejected the Shafer Commission's findings and escalated cannabis enforcement. In a 1994 interview, his domestic policy chief John Ehrlichman explicitly confirmed that the War on Drugs was designed to target the anti-war left and Black communities: "Did we know we were lying about the drugs? Of course we did." This admission, made decades after the fact, confirmed what critics had long argued — that cannabis prohibition was fundamentally a tool of political repression rather than public health protection.

President Nixon formally declared the "War on Drugs" in June 1971, describing drug abuse as "public enemy number one" and establishing the Drug Enforcement Administration (DEA) in 1973. Cannabis was placed in Schedule I of the Controlled Substances Act — alongside heroin — classifying it as having no accepted medical use and high potential for abuse. This classification has remained unchanged by federal law in the United States to this day, though dozens of states have independently legalised medical and recreational cannabis.

The consequences of this policy were enormous and fell disproportionately on Black and Latino communities despite comparable rates of cannabis use across racial groups. Studies have consistently shown that Black Americans are arrested for cannabis possession at roughly 3.7 times the rate of white Americans, despite similar usage rates. Between 1965 and 2020, cannabis arrests in the United States exceeded 20 million — a figure that dwarfs the populations of most countries.

The United Nations Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971) extended the prohibition framework globally, pressuring signatory nations to criminalise cannabis regardless of their domestic traditions or evidence base. Countries that had ancient relationships with cannabis — India with bhang, Morocco with kif, Jamaica with ganja — found themselves pressured to impose criminal penalties on practices that had existed for centuries.

The financial cost of cannabis prohibition has been staggering. Studies estimated that the United States alone spent approximately $3.6 billion annually on cannabis enforcement at federal and state levels through the 2000s. The human cost — in incarcerated lives, destroyed employment records, family separations, and communities stripped of men and women to the prison system — is beyond calculation. The academic consensus by the early 2010s was nearly universal: prohibition had failed by every meaningful measure.

The rediscovery of cannabis as a legitimate medicine began with a series of scientific breakthroughs in the 1980s and 1990s that established the biological basis for its therapeutic effects. In 1988, DEA Administrative Law Judge Francis Young, after extensive review of evidence, ruled that "marijuana is one of the safest therapeutically active substances known to man" and recommended it be rescheduled for medical use — a recommendation that the DEA rejected.

Raphael Mechoulam of Hebrew University in Jerusalem had identified and synthesised THC in 1964 and CBD in 1963, but the true turning point came in 1988 when researchers at St. Louis University identified specific receptors in the human brain that responded to cannabinoids — the first evidence that the body has an endogenous system designed to interact with cannabis compounds. In 1992, Mechoulam and his team discovered anandamide — the body's own cannabis-like molecule — and the endocannabinoid system (ECS) was formally established.

Understanding the ECS changed everything. It became clear that cannabinoids were not foreign intoxicants disrupting an otherwise orderly brain chemistry, but rather compounds that modulated a system of receptors evolved over hundreds of millions of years. The therapeutic implications were profound: the ECS regulates pain, immune function, mood, memory, appetite, sleep, and reproductive function, making it a target of extraordinary pharmaceutical interest.

California passed Proposition 215 in 1996 — the Compassionate Use Act — becoming the first U.S. state to legalise medical cannabis. Patients with AIDS wasting syndrome, cancer, and other serious conditions had been advocating for legal access for years, most notably through Dennis Peron's work in San Francisco during the AIDS crisis. The measure passed with 56% of the vote. Over the next decade, medical cannabis laws spread to 12 more states, establishing a legal patchwork that would eventually pressure federal reform.

The Netherlands established what became the world's most famous cannabis policy in 1976 through the Opium Act revision that introduced the concept of "gedoogbeleid" — a formal tolerance policy under which the possession and retail sale of small amounts of cannabis were officially tolerated, though not legalised. The legal distinction is important: cannabis remained technically illegal in the Netherlands, but prosecution was suspended for both individual possession and for licensed coffee shops selling quantities under five grams.

The first coffee shop to operate under this framework, Mellow Yellow, opened in Amsterdam in 1972, predating the formalisation of the policy. By the 1980s, Amsterdam had developed a thriving coffee shop culture that attracted tourists from across Europe and the world. At peak market in the 1990s, over 1,500 coffee shops operated across the Netherlands. Dutch tolerance created the world's first legitimate cannabis retail market and, critically, the world's first legal framework for quality control and consumer safety.

The Paradox of Dutch policy — retail sales tolerated, cultivation illegal — created the infamous "back-door problem": coffee shops could legally sell cannabis but could not legally source it. This forced shops to purchase from illegal wholesale suppliers, creating a grey market that persists to the present day and has been a subject of ongoing political negotiation. The Netherlands began a controlled cultivation experiment in 2023 to address this supply-chain inconsistency.

The Amsterdam model profoundly influenced cannabis reform globally, demonstrating that tolerance of cannabis retail could exist alongside a functioning society without the catastrophic consequences predicted by prohibitionists. Research consistently showed that Dutch youth cannabis use rates were not significantly higher than in comparable prohibitionist countries, undermining one of the central arguments against reform.

Colorado and Washington State passed ballot initiatives legalising recreational cannabis in November 2012, marking the beginning of the modern legalisation era. For the first time in the world, a democratic government had mandated the legal commercial sale of cannabis to adults for recreational purposes — not mere decriminalisation or medical access, but full legal retail markets with licensed dispensaries, regulated production, and substantial tax revenue.

The Colorado experiment delivered results that surprised many observers. Cannabis tax revenues exceeded projections significantly — Colorado has collected over $1.9 billion in cannabis taxes since 2014 — while youth cannabis use rates remained stable. Traffic fatalities showed no significant increase attributable to cannabis. The predicted social collapse failed to materialise. Academic and policy researchers from around the world descended on Colorado to study what was, in effect, the largest controlled experiment in cannabis policy reform in human history.

Canada became the first G7 nation to fully legalise recreational cannabis nationally when the Cannabis Act came into force on 17 October 2018. Prime Minister Justin Trudeau's government implemented a comprehensive federal framework covering production, distribution, retail, and consumption. The transition was not without difficulties — initial supply shortages, inconsistent quality standards, and the competitive disadvantage faced by the legal market relative to the established illegal market — but by 2020 the legal market had substantially matured.

Germany passed landmark legislation in 2024 allowing adults to possess up to 50 grams of cannabis and grow up to three plants personally, while establishing a framework for licensed cannabis clubs. The German reform was significant as the largest European economy to move toward legalisation and created substantial pressure on neighbouring EU member states to reconsider their own policies. Malta had already become the first EU member to legalise personal possession and home growing in 2021, while Luxembourg followed in 2023.

The 20th century prohibition of cannabis created the paradoxical situation of also criminalising industrial hemp — the non-psychoactive fibre and seed variety that had served human economies for 10,000 years. THC content thresholds (typically 0.2–0.3%) were established in various jurisdictions as the legal boundary between hemp and marijuana, but enforcement challenges led many countries to simply prohibit all Cannabis cultivation regardless of THC content.

The rehabilitation of industrial hemp began in the 1990s and has accelerated dramatically. The EU legalised hemp cultivation in 1993 and Canada permitted it from 1998. The United States finally legalised industrial hemp cultivation nationally through the 2018 Farm Bill, removing hemp from the Controlled Substances Act and opening a market that had been effectively closed for over 80 years.

The contemporary hemp industry encompasses textiles, food products (hemp seeds are among the most nutritionally complete plant foods available), building materials (hempcrete — a concrete-like material made from hemp hurds — is gaining significant traction as a sustainable construction material), paper, biodegradable plastics, biofuel, and an expanding pharmaceutical sector. Hemp-derived CBD (cannabidiol) became a global consumer phenomenon in the late 2010s, with the global CBD market estimated to reach $47 billion by 2028.

The environmental case for hemp is compelling. As a rotation crop, hemp improves soil quality, requires minimal pesticide input compared to cotton, can be grown in temperate climates globally, and produces biomass at rates rivalling purpose-grown energy crops. Researchers at various institutions have documented hemp's potential as a carbon sink, absorbing more CO₂ per hectare than most trees. The plant that clothed and equipped ancient civilisations for millennia is re-emerging as a potential answer to some of the most pressing environmental challenges of the 21st century.

The scientific understanding of why cannabis affects the human body as it does required decades of painstaking research and the overcoming of significant political barriers. Raphael Mechoulam and his colleagues at the Hebrew University of Jerusalem isolated and synthesised THC in 1964 and CBD in 1963, establishing for the first time the precise chemical structures of the compounds responsible for cannabis's effects. This work, funded partly by the Israeli government and conducted openly during an era when cannabis research was heavily restricted elsewhere, laid the groundwork for everything that followed.

The identification of cannabinoid receptors in the human brain in 1988 by Allyn Howlett and William Devane at St. Louis University was a turning point. If the brain had specific receptors for THC, it logically followed that the brain produced its own compounds to activate those receptors — and in 1992, Mechoulam's team identified anandamide, naming it after the Sanskrit word for bliss. The endocannabinoid system (ECS) — comprising CB1 receptors (primarily in the brain and nervous system), CB2 receptors (primarily in the immune system), and the endogenous cannabinoids that activate them — was now formally established.

The ECS modulates an extraordinary range of physiological processes: pain transmission, inflammation, immune response, mood regulation, memory formation and extinction, appetite, sleep-wake cycles, stress response, and reproductive function. Its ubiquity across mammalian biology — it is present in every vertebrate species studied — suggests it evolved very early and serves fundamental regulatory functions. This explains the breadth of cannabis's therapeutic potential: it is not that cannabis treats a long list of unrelated conditions, but rather that modulating the ECS affects multiple physiological systems simultaneously.

Current ECS research is among the most active frontiers in pharmacology. Over 20,000 scientific papers on cannabinoids and the endocannabinoid system were published between 2010 and 2024. Pharmaceutical applications range from nabilone (a synthetic THC analogue used for chemotherapy nausea), to nabiximols (THC:CBD combination approved in several countries for MS spasticity), to the CBD-derived epilepsy treatment Epidiolex (FDA-approved 2018 for treatment-resistant childhood epilepsies). The full therapeutic potential of the ECS remains incompletely explored.

Cannabis policy in the 2020s presents a genuinely novel picture: a substance that was globally prohibited within living memory now legally sold in licensed stores across North America, large parts of Europe, and a growing number of jurisdictions worldwide. The trajectory of reform — while uneven and subject to political reversal — has maintained a consistent direction toward legalisation in democratic societies where the question has been put to referendum or substantive legislative debate.

The scientific understanding of cannabis has transformed in parallel with the policy landscape. The 2018 FDA approval of Epidiolex (a purified CBD product) for two rare forms of childhood epilepsy represented the first cannabis-derived pharmaceutical to receive full FDA approval, and validated decades of patient and advocacy community reports about CBD's anticonvulsant properties. Clinical trials ongoing as of 2024 are investigating cannabinoids for PTSD, chronic pain, multiple sclerosis, Parkinson's disease, inflammatory bowel disease, and cancer symptom management.

The global cannabis market — combining medical, recreational, and hemp sectors — is projected to reach $100 billion by 2030. This commercialisation brings both opportunities and concerns. Concerns about industry consolidation, the replacement of small cultivators by large corporations, product safety standards, advertising practices, and the persistence of racial inequities in cannabis enforcement even as markets open, have all become prominent topics in policy discourse.

The UN Commission on Narcotic Drugs voted in December 2020 to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs (the most restrictive classification), acknowledging its medical value while retaining it in Schedule I. This modest but symbolically significant change marked the first time in 59 years that the international community had formally updated its classification of cannabis, reflecting the accumulated weight of scientific evidence that could no longer be ignored.